Apremilast Efficacy Results Disappoint But May Be Enough For Commercial Success
This article was originally published in The Pink Sheet Daily
Celgene’s PDE-4 inhibitor met the primary endpoint in the first of two pivotal Phase III trials, but analysts worried that the treatment effect was less than that seen in a Phase II study. Some analysts still see a strong niche position for apremilast in treatment-naïve patients before they move on to biologic therapy.
You may also be interested in...
The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.
The biotech did better than Wall Street expected with its first sales figures for multiple myeloma drug Pomalyst. But it’s still very early going. Continuing to expand its hematology oncology franchise, including main revenue-driver Revlimid, remains a primary focus for Celgene.
Celgene reported strong sales for key products, led by Revlimid, during its year-end 2012 call. The biopharma affirmed 2013 guidance, detailing the key regulatory and commercial drivers that will power the global expansion of its hematology, oncology, and immunology franchises. In particular, it highlighted the commercial potential for apremilast.